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ABSTRACT
Demonstration projects or pilots of new public health interventions aim to build learning and capacity to
inform country-wide implementation. Authors examined the value of HPV vaccination demonstration
projects and initial national programmes in low-income and lower-middle-income countries, including
potential drawbacks and how value for national scale-up might be increased. Data from a systematic
review and key informant interviews, analyzed thematically, included 55 demonstration projects and 8
national programmes implemented between 2007-2015 (89 years’ experience). Initial demonstration
projects quickly provided consistent lessons. Value would increase if projects were designed to inform
sustainable national scale-up. Well-designed projects can test multiple delivery strategies, implementation
for challenging areas and populations, and integration with national systems. Introduction of vaccines or
other health interventions, particularly those involving new target groups or delivery strategies, needs
ﬂexible funding approaches to address speciﬁc questions of scalability and sustainability, including







Demonstration projects or pilots of new public health interven-
tions are widely used.1 Geographically and time-limited, they
aim to build learning and capacity to inform country-wide
implementation.1,2 Between 2007 and 2011, demonstration
projects were the main approach to delivering new vaccines
against human papillomavirus (HPV) to prevent cervical can-
cer in low-income and lower-middle-income countries
(LLMICs).3,4 Initial pilots, with vaccines donated by Merck &
Co., Inc. or GlaxoSmithKline Biologicals to governments and
external partners, allowed countries to gain experience vacci-
nating adolescent girls, who were not routinely targeted for
immunisation.5,6 With the exception of Rwanda and Bhutan,
vaccine donations for national delivery were not generally
available, so demonstration projects enabled resource-poor
countries to gain HPV vaccination experience.7,8
From late 2012, Gavi, the Vaccine Alliance, began supporting
HPV vaccination demonstration projects or national pro-
grammes if countries had prior experience vaccinating girls aged
9–13.9 The principle objective of Gavi support was to ‘learn by
doing’. Gavi provided 2-year funding for vaccines and opera-
tional costs to allow time to assess delivery strategies and poten-
tial integration with other adolescent services, develop tools, and
prepare applications to Gavi for national program funding. By
mid-2015, Gavi had approved demonstration project funding
for 25 countries, of which 6 (24%) had already conducted at least
one pilot, while another 3 were approved for national support.9
Despite 55 pilots or demonstration projects being completed
before 2015, only 7 countries – and 3more in 2015-2016 - transi-
tioned from demonstration to national provision.2,10
This article aims to examine the value of HPV vaccination
demonstration projects to date, including potential drawbacks
and how value for informing national scale-up might be
increased, drawing from a review of published and unpublished
documents from 37 countries and key informant interviews
from 23 countries conducted in 2015.2 Countries with data in
the public domain are speciﬁcally named, while others were
anonymised with an identiﬁcation number. Lessons are rele-
vant for countries intending to introduce HPV vaccination and
more broadly for funders supporting introduction of new
health interventions in LLMICs.
Value and drawbacks of demonstration projects
Demonstration projects allowed both national and external
partners to gain valuable experience in planning and budgeting
for a new intervention, enumerating target populations, devel-
oping community acceptability and consent procedures for
adolescent services, designing and piloting new reporting forms
and systems, coordinating with the Ministry of Education for
school-based vaccination, and using standardised evaluation
tools.11-13
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While countries had nuanced experiences and gained from
the ‘learning by doing’ process, lessons from later demonstra-
tion projects generally repeated those reported earlier,2 indicat-
ing that while individual countries might require ﬁrst-hand
experience, sufﬁcient collective learning has been generated.
Several drawbacks of demonstration projects were noted.
First, the limited scale of projects did not allow assessment of
potential health system integration, particularly as demonstra-
tion projects were often implemented outside routine services.
Second, communication and social mobilisation activities had
to be carefully restricted to avoid perceived inequity among
those not receiving vaccination. Third, ‘demonstration project’
was an unclear term for many stakeholders with some commu-
nities concluding that the vaccine rather than delivery method
was being piloted. Fourth, many were conducted in areas pri-
marily selected for convenience (e.g. with higher routine vacci-
nation coverage, more extensive infrastructure, and better
education levels than national averages), potentially providing
few lessons applicable to national scale-up. Fifth, the resource-
intensive delivery strategies used in demonstration projects
were potentially unsustainable once vaccine donations and
external support for operational costs ended. Finally, demon-
stration planning was sometimes as intensive as that for
national programming.
Thus, opportunities to explore novel or sustainable deliv-
ery strategies were often missed. A focus on project evalua-
tion and demonstrating at least 50% vaccination coverage to
secure Gavi support for national introduction, led some
countries to choose safe options (e.g., school-based delivery)
known for achieving good coverage but potentially too costly
to be sustainably expanded nationally. Few projects purpose-
fully included hard-to-reach girls.14 Projects in only 3 coun-
tries simultaneously or sequentially tested different
vaccination venues, only 2 simultaneously tested different
eligibility criteria,15,16 and only one tested different vaccina-
tion timings.16 As approximately 13 projects tested HPV vac-
cination integration (e.g. with tetanus toxoid vaccination,
deworming, vitamin A supplementation, health education),
learning around combination interventions was largely
missed.
Increasing the value of demonstration projects for
national scale-up
Many of the drawbacks above seemed to originate from design
choices. Value would increase substantially if projects were
designed to learn speciﬁc lessons and inform realistic national
scale-up. For example, the prevailing ‘learning by doing’ objec-
tive appeared disconnected from learning for national scale-up,
while ‘attaining good coverage,’ as a performance indicator for
funding allocation, could create distortions similarly unsuppor-
tive of learning for scale-up. Instead, countries could test and
cost different delivery strategies in different districts simulta-
neously, e.g., school-based and health facility-based, to inform
sustainable national expansion.16 Alternatively, donors could
fund further economic modeling of different strategies to
inform both demonstration projects and national scale-up.
Evaluation is critical for any testing approach and cost and cov-
erage evaluations were included in a few demonstration
projects. However, evaluations often lacked sufﬁcient evidence
to inform decision-making, with data missing or derived from
pre-set grants that generally magniﬁed operational costs.
Twenty completed demonstration projects before 2015 with-
out announcing plans to scale-up, 5 of which ceased imple-
menting HPV vaccination without attempting to co-ﬁnance
vaccine and operational costs, 2 conducted further demonstra-
tion projects, and the remainder have not indicated a decision.
Implementation often stalled due to vaccine donations ending,
funding constraints, or lack of ownership by national immuni-
sation programmes. Demonstration projects may thus delay
decision-making or even discourage national scale-up due to
the high-cost strategies tested during the demonstration phase.
Lessons from demonstration projects were not always rele-
vant to scale-up. Of seven LLMICs that scaled-up from demon-
stration to national implementation, only one reported that
project lessons were useful for expansion, while another
reported national expansion as more valuable for testing possi-
ble implementation strategies. Several indicated that demon-
stration projects were too small to inform national expansion
or selected a different delivery strategy than had been tested.
Several countries implemented successive demonstration
projects. Of these, 3 used lessons from Gardasil Access Program
(GAP) projects to test different delivery strategies as part of
Gavi-funded demonstration projects while 6 conducted multi-
ple, sequential non-Gavi projects for reasons unclear from the
data. While some scale-up delays are probably due to insufﬁ-
cient national immunisation program engagement with early
demonstration projects, an overall discontinuity exists between
implementing demonstration projects and national expansion.
Longer-term comprehensive planning of projects and expan-
sion, or changing to phased national introduction approaches,
could accelerate scale-up.
The pathway from demonstration to scale-up is not straight-
forward and major challenges to sustainability persist. Financial
sustainability was identiﬁed as the main barrier to scale-up.
Interviewees indicated that the expensive campaign-style deliv-
ery and reduced external support during scale-up challenged
national expansion efforts. However, the question remains
whether demonstration projects may have become a way to
delay or discourage commitment to scale-up. With many les-
sons already from 55 demonstration projects, learning may be
saturated and further learning likely to be most effective during
national implementation, or in the context of phased national
expansion. This would maintain political commitment to scale-
up and avoid loss of integration with national health systems.
Conclusions
Well-designed demonstration projects can test multiple deliv-
ery strategies, implementation for challenging areas and popu-
lations, and integration with national systems.16-18 Countries
implementing new interventions beneﬁt through ‘learning by
doing’ and may need initial experiences to hone social mobili-
sation, delivery strategies, and reporting. However, demonstra-
tions can distract momentum from national introduction and
designs that test alternative scalable options are thus crucial.
Demonstration projects were valuable when HPV vaccine was
ﬁrst offered to LLMICs before national funding was available.
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However, with many lessons already documented, few new les-
sons observed, and additional funding available, their value has
decreased. Projects were designed to ‘demonstrate’ whether
LLMICs could implement HPV vaccination rather than
whether they could implement it sustainably and at scale.
While the latter is crucial, countries were reportedly reluctant
to risk experimenting and potentially lose funding.
In the example of HPV vaccination, initial demonstration proj-
ects quickly provided consistent lessons. However, scale-up is criti-
cal to maximise health impact, and further demonstrations could
distractmomentum and decision-making. Any new demonstration
projects should have guidelines that maximise value for national
implementation, and ﬂexibility for phased transition to national
scale-up, without repeated funding applications. Thus, introduc-
tion of vaccines or other interventions, particularly those involving
new target groups or delivery strategies, needs ﬂexible funding
approaches so that pilots can address speciﬁc questions of scalabil-
ity and sustainability. This could include phased national introduc-
tion. Lessons fromHPV vaccine introduction are relevant for other
potential interventions that may be introduced in the coming years
(e.g., MenACWY vaccine, RTS, S vaccine).
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